The controversial approval of an antisense drug for muscular dystrophy dominated news this quarter, with overall approvals down compared with recent years. Two biosimilars made it over the finish line at the US Food and Drug Administration (FDA), and the European Medicines Agency (EMA) approved a genetically modified allogeneic T-cell therapy for use in bone marrow/stem cell transplants. A slew of breakthrough designations included two gene therapies; December looks to be a busy month at the FDA.

Historic FDA approvals by drug type

Notable setbacks (3Q16)

Notable clinical trial results (3Q16)

Notable regulatory approvals (3Q16)

Notable upcoming catalysts (4Q16)